Delayed gastric emptying in Parkinson's disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Gastrointestinal symptoms are evident in all stages of Parkinson's disease (PD). Most of the gastrointestinal abnormalities associated with PD are attributable to impaired motility. At the level of the stomach, this results in delayed gastric emptying. The etiology of delayed gastric emptying in PD is probably multifactorial but is at least partly related to Lewy pathology in the enteric nervous system and discrete brainstem nuclei. Delayed gastric emptying occurs in both early and advanced PD but is underdetected in routine clinical practice. Recognition of delayed gastric emptying is important because it can cause an array of upper gastrointestinal symptoms, but additionally it has important implications for the absorption and action of levodopa. Delayed gastric emptying contributes significantly to response fluctuations seen in people on long‐term l‐dopa therapy. Neurohormonal aspects of the brain‐gut axis are pertinent to discussions regarding the pathophysiology of delayed gastric emptying in PD and are also hypothesized to contribute to the pathogenesis of PD itself. Ghrelin is a gastric‐derived hormone with potential as a therapeutic agent for delayed gastric emptying and also as a novel neuroprotective agent in PD. Recent findings relating to ghrelin in the context of PD and gastric emptying are considered. This article highlights the pathological abnormalities that may account for delayed gastric emptying in PD. It also considers the wider relevance of abnormal gastric pathology to our current understanding of the etiology of PD. © 2013 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“Ghrelin is an endogenous 28–amino acid peptide, first described in 1999.(85) It is produced in the stomach but the growth hormone secretagogue receptors (GHSR), at which it acts, have been identified in numerous sites within the GI tract, the ENS, and also the CNS.”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354 · cited 1×
“Aggregated a-synuclein in the gastric wall (Braak et al.(11) Neu-”
BackgroundArizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Frequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738
A timeline for Parkinson's disease
Hawkes, C. H., Del Tredici, K., & Braak, H. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.08.007 · Cited by 594
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Soykan, I., Sivri, B., Sarosiek, I., Kiernan, B., & Mccallum, R. W. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026665728213 · Cited by 575 · cited 1×
“5% of all cases.(53,54) In the general population, the prevalence of gastroparesis is estimated to be 9.”
BackgroundJung, H., Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., Szarka, L. A., Mullan, B., & Talley, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.047 · Cited by 571
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · cited 1×
“More recently a proof of concept study of the GLP-1 agonist exenatide in 45 patients with moderate PD reported improvements in motor function over 12 months of treatment.(33) Alpha-Synuclein and the Stomach in PD”
BackgroundPan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524 · cited 2×
“Mice chronically exposed to rotenone have been shown to develop alpha-synuclein inclusions within the Movement Disorders, Vol. 29, No. 1, 2014 25 myenteric plexus.48 Additionally, direct intragastric rotenone administration in rodents not only led to alpha-synuclein accumulation in the ENS but also remotely in the DMN…”
Pan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'Sullivan, G. A., Pal, A., Said, J., Marsico, G., Verbavatz, J.-M., Rodrigo-Angulo, M., et al. (2012) · Scientific Reports · doi:10.1038/srep00898 · Cited by 405
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380
Abell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361 · cited 1×
“Finally, dietary adjustments such as reducing meal volume while increasing meal frequency (“little and often”) has been advocated as a useful approach in gastroparesis generally.(109)”
BackgroundCersosimo, M. G., Raina, G. B., Pecci, C., Pellene, A., Calandra, C. R., Gutiérrez, C., Micheli, F. E., & Benarroch, E. E. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6801-2 · Cited by 314
Parkinson's Disease: The Dual Hit Theory Revisited
Hawkes, C. H., Del Tredici, K., & Braak, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04365.x · Cited by 303
Andrews, Z. B., Erion, D., Beiler, R., Liu, Z.-W., Abizaid, A., Zigman, J., Elsworth, J. D., Savitt, J. M., DiMarchi, R., Tschöp, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3890-09.2009 · Cited by 289
Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo
Angot, E., Steiner, J. A., Lema Tomé, C. M., Ekström, P., Mattsson, B., Björklund, A., & Brundin, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039465 · Cited by 270
Gastric emptying time and gastric motility in patients with Parkinson's disease
Hardoff, R., Sula, M., Tamir, A., Soil, A., Front, A., Badarna, S., Honigman, S., & Giladi, N. (2001) · Movement Disorders · doi:10.1002/mds.1203 · Cited by 248
The physiology of gastric emptying
Hellström, P. M., Grybäck, P., & Jacobsson, H. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2006.02.002 · Cited by 223
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199
Gastroparesis and Parkinson’s disease: a systematic review
Heetun, Z. S., & Quigley, E. M. M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.12.004 · Cited by 182
Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra
Jiang, H., Li, L.-J., Wang, J., & Xie, J.-X. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.05.006 · Cited by 144
Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease
Lee, W. Y., Yoon, W. T., Shin, H. Y., Jeon, S. H., & Rhee, P. (2008) · Movement Disorders · doi:10.1002/mds.22190 · Cited by 110 · cited 2×
“However, there is evidence to suggest that such colonization may also contribute to motor fluctuations.(83) Following H.”
BackgroundUnger, M. M., Möller, J. C., Mankel, K., Eggert, K. M., Bohne, K., Bodden, M., Stiasny-Kolster, K., Kann, P. H., Mayer, G., Tebbe, J. J., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5864-1 · Cited by 97
Gastrointestinal features of Parkinson’s disease
Cloud, L. J., & Greene, J. G. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0204-0 · Cited by 67
The influence of levodopa on gastric emptying in healthy elderly volunteers
Robertson, D. R. C., Renwick, A. G., Macklin, B., Jones, S., Waller, D. G., George, C. F., & Fleming, J. S. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280127 · Cited by 45
Gastric emptying in healthy volunteers after multiple doses of levodopa
Waller, D., Roseveare, C., Renwick, A., Macklin, B., & George, C. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03975.x · Cited by 17
Cited by
NADPH oxidase in brain injury and neurodegenerative disorders
Ma, M. W., Wang, J., Zhang, Q., Wang, R., Dhandapani, K. M., Vadlamudi, R. K., & Brann, D. W. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0150-7 · Cited by 432
Chen, Z., Li, G., & Liu, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 363
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
“Delayed gastric emptying in PD patients dampens the proper absorption of levodopa or dopamine agonists, causing lower peak plasma concentrations and on-off fluctuations of the drug (Doi et al., 2012; Hardoff et al., 2001; Marrinan et al., 2013).”
BackgroundGastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments
Poirier, A.-A., Aubé, B., Côté, M., Morin, N., Di Paolo, T., & Soulet, D. (2016) · Parkinson s Disease · doi:10.1155/2016/6762528 · Cited by 130
“Although the ENS has the ability to function independently of external stimuli, it also closely interacts with the vagal system [39, 41].”
Background
Metadata
- Authors
- Marrinan, S., Emmanuel, A. V., & Burn, D. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2013-10-21
- Volume
- 29
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1886198396
- Cited by
- 156
- References
- 30
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.